RBC Capital Maintains Outperform on Ambrx Biopharma, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Ambrx Biopharma (NASDAQ:AMAM) but reduced the price target from $33 to $32.

November 14, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst reaffirms Outperform rating on Ambrx Biopharma but lowers price target from $33 to $32.
The reduction in price target is marginal, suggesting that the analyst's overall positive view on the company remains intact. The Outperform rating indicates a belief that the stock will perform better than the market or sector average. However, the price target cut could signal a slight adjustment in expectations, possibly due to market conditions or revised estimates on the company's future performance. This news is likely to have a neutral short-term impact on the stock price as the reaffirmation of the Outperform rating balances the minor negative sentiment from the reduced price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100